Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
XPHOZAH - tenapanor for phosphate control in adults on dialysis
Product / population
XPHOZAH oral tenapanor; phosphate-control indication. Not IBSRELA for IBS with constipation.
Renal method
Adults with CKD already on dialysis; phosphorus response, tolerability and dialysis timing.
Source revision
Source revision date not established in selected retrieval.
Retrieved
2026-09-07
Local review status
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
Dialysis indication and interaction rules matter separately from clearance
XPHOZAH is a phosphate-control product for selected adults with CKD on dialysis, not a universal renal-adjustment instruction for tenapanor. Its source also contains specific separation and enalapril interaction instructions.
What to reconcile: Confirm the phosphate-binder context, dialysis timing and interacting medicines. The enalapril statement must not be generalized to other ACE inhibitors or used as an automatic dose increase.
DailyMed · XPHOZAH oral tenapanor; phosphate-control indication. Not IBSRELA for IBS with constipation.
Renal method: Adults with CKD already on dialysis; phosphorus response, tolerability and dialysis timing. Source date: Source revision date not established in selected retrieval. Retrieved: 2026-09-07
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
For adult CKD patients on dialysis with inadequate response to phosphate binders or intolerance of any binder dose, the labeled regimen is 30 mg orally twice daily before morning and evening meals. Monitor phosphorus and adjust for gastrointestinal tolerability. Do not take immediately before hemodialysis; take before the next meal after dialysis because diarrhea can follow administration. Stop treatment for severe diarrhea. Separate sodium polystyrene sulfonate by at least 3 hours. Review OATP2B1 interactions, particularly enalapril: the label contains an exception to the usual lower starting-dose advice when coadministered. The dialysis-specific indication is not a general CKD or IBSRELA dosing recommendation.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.